{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:46:59Z","timestamp":1791946019373,"version":"4.3.4"},"reference-count":122,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Basic and Clinical Collaborative Research Program of Anhui Medical University","award":["2022xkjT020"],"award-info":[{"award-number":["2022xkjT020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Vitiligo is a chronic autoimmune disorder with a multifactorial etiology, typically manifesting as localized or generalized hypopigmentation or depigmentation of the skin and mucous membranes. The pathogenesis of vitiligo is complex and significantly impacts patients\u2019 quality of life. Although traditional treatments such as hormone therapy, topical medications, and laser therapy can help control the disease to some extent, their outcomes remain unsatisfactory. Therefore, ongoing research is crucial to explore and develop novel treatment strategies while assessing their efficacy and safety. This review aims to classify and summarize various new candidate drugs for vitiligo currently undergoing clinical trials, providing a reference for clinical practice. Recent advancements in the understanding of the pathogenesis of vitiligo have facilitated the development of potential treatment strategies, such as Janus kinase inhibitors, cytokine blockers, and agents targeting tissue-resident memory or regulatory T cells. These emerging therapies offer hope to patients with vitiligo, though further investigation is needed to confirm their safety, efficacy, and optimal treatment regimens.<\/jats:p>","DOI":"10.3390\/cimb47030191","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T13:07:51Z","timestamp":1741957671000},"page":"191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Emerging Therapeutic Innovations for Vitiligo Treatment"],"prefix":"10.3390","volume":"47","author":[{"given":"Weiran","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, China"},{"name":"Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou 215128, China"},{"name":"Key Laboratory of Dermatology, Ministry of Education of the People\u2019s Republic of China, Hefei 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penghao","family":"Dong","sequence":"additional","affiliation":[{"name":"Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, China"},{"name":"Key Laboratory of Dermatology, Ministry of Education of the People\u2019s Republic of China, Hefei 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, China"},{"name":"Key Laboratory of Dermatology, Ministry of Education of the People\u2019s Republic of China, Hefei 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, China"},{"name":"Key Laboratory of Dermatology, Ministry of Education of the People\u2019s Republic of China, Hefei 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei 230000, China"},{"name":"Department of Dermatology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou 215128, China"},{"name":"Key Laboratory of Dermatology, Ministry of Education of the People\u2019s Republic of China, Hefei 230000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: A Review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"ref_2","first-page":"CD003263","article-title":"Interventions for vitiligo","volume":"2015","author":"Whitton","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1468-3083.2006.01897.x","article-title":"Stigmatization experience, coping and sense of coherence in vitiligo patients","volume":"21","author":"Kunsebeck","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2133.2005.06456.x","article-title":"Effect of vitiligo on self-reported health-related quality of life","volume":"152","author":"Ongenae","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental Health and Psychosocial Quality-of-Life Burden Among Patients with Vitiligo: Findings from the Global VALIANT Study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0378-6323.32708","article-title":"Vitiligo: Compendium of clinico-epidemiological features","volume":"73","author":"Sehgal","year":"2007","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/exd.13677","article-title":"The convergence theory for vitiligo: A reappraisal","volume":"28","author":"Kundu","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: The role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2174\/1389450123666220406125645","article-title":"Current Debates on Etiopathogenesis and Treatment Strategies for Vitiligo","volume":"23","author":"Chaudhary","year":"2022","journal-title":"Curr. Drug Targets"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/ced\/llad188","article-title":"Emerging role of topical Janus kinase inhibitors in dermatological disorders: A review","volume":"48","author":"Dogra","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104499","DOI":"10.1016\/j.amsu.2022.104499","article-title":"FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1401867","article-title":"Mechanisms of Jak\/STAT signaling in immunity and disease","volume":"194","author":"Villarino","year":"2015","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK Expression in Vitiligo","volume":"25","author":"Tawfik","year":"2021","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_17","first-page":"343","article-title":"Interfering with the IFN-gamma\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Qi, F., Liu, F., and Gao, L. (2021). Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.790125"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_20","first-page":"394","article-title":"Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis","volume":"13","author":"Mesa","year":"2010","journal-title":"IDrugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1159\/000514535","article-title":"Biological Therapies for Atopic Dermatitis: A Systematic Review","volume":"237","author":"Zhou","year":"2021","journal-title":"Dermatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15593258221105370","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Seneschal, J., Guyon, M., Merhi, R., Mazereeuw-Hautier, J., Andreu, N., Cazenave, S., Ezzedine, K., Passeron, T., and Boniface, K. (2025). Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo: A Randomized Clinical Trial. JAMA Dermatol., Advance online publication.","DOI":"10.1001\/jamadermatol.2024.5737"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2200873","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: A case report","volume":"34","author":"Pan","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.jaad.2023.07.1016","article-title":"Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo","volume":"89","author":"Su","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/1346-8138.17064","article-title":"Alopecia areata: What\u2019s new in the diagnosis and treatment with JAK inhibitors?","volume":"51","author":"Dainichi","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ni.2744","article-title":"The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin","volume":"14","author":"Mackay","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","first-page":"e14029","article-title":"Vitiligo: The Association with Metabolic Syndrome and the Role of Simvastatin as an Immunomodulator","volume":"13","author":"Verma","year":"2021","journal-title":"Cureus"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-3-7","article-title":"Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo","volume":"3","author":"Noel","year":"2004","journal-title":"Lipids Health Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e15969","DOI":"10.1111\/dth.15969","article-title":"Simvastatin and non-segmental vitiligo: A new potential treatment option?","volume":"35","author":"Shaker","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/jim-2020-001390","article-title":"Efficacy and safety of oral simvastatin in the treatment of patients with vitiligo","volume":"69","author":"Zhang","year":"2021","journal-title":"J. Investig. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jaad.2016.06.015","article-title":"A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo","volume":"76","author":"Vanderweil","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jid.2017.01.020","article-title":"Simvastatin Protects Human Melanocytes from H2O2-Induced Oxidative Stress by Activating Nrf2","volume":"137","author":"Chang","year":"2017","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jamadermatol.2017.6401","article-title":"Atorvastatin in Combination with Narrowband UV-B in Adult Patients with Active Vitiligo: A Randomized Clinical Trial","volume":"154","author":"Nguyen","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-018-3168-4","article-title":"The Evaluation of Vitiligous lesions Repigmentation after the Administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo (EVRAAS), a pilot study: Study protocol for a randomized controlled trial","volume":"20","author":"Niezgoda","year":"2019","journal-title":"Trials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1111\/bjd.15550","article-title":"Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: Relevance for cutaneous lupus and vitiligo pathogenesis","volume":"177","author":"Jacquemin","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1755-148X.2011.00916.x","article-title":"HSP70i is a critical component of the immune response leading to vitiligo","volume":"25","author":"Mosenson","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000001003","article-title":"Emerging biologic therapies for systemic lupus erythematosus","volume":"36","author":"Kato","year":"2024","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata","volume":"89","author":"Zhou","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/jid.2014.527","article-title":"Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: A randomized, double blind, placebo-controlled study","volume":"135","author":"Cavalie","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.autrev.2014.10.002","article-title":"Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics","volume":"14","author":"Dwivedi","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41435-023-00221-y","article-title":"IL-2 immunotherapy for targeting regulatory T cells in autoimmunity","volume":"24","author":"Lykhopiy","year":"2023","journal-title":"Genes Immun."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Tokura, Y., Phadungsaksawasdi, P., Kurihara, K., Fujiyama, T., and Honda, T. (2020). Pathophysiology of Skin Resident Memory T Cells. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.618897"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/jocd.13908","article-title":"Elevated serum level of interleukin-15 in vitiligo patients and its correlation with disease severity but not activity","volume":"20","author":"Atwa","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2468-1253(19)30265-1","article-title":"Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: A phase 2a, randomised, double-blind, placebo-controlled, parallel-group study","volume":"4","author":"Cellier","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/exd.13069","article-title":"Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo","volume":"26","author":"Speeckaert","year":"2017","journal-title":"Exp. Dermatol."},{"key":"ref_63","first-page":"CD007277","article-title":"Abatacept for rheumatoid arthritis","volume":"2009","author":"Maxwell","year":"2009","journal-title":"Cochrane Database Syst Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/pcmr.12105","article-title":"Decreased regulatory T-cells and CD4+\/CD8+ ratio correlate with disease onset and progression in patients with generalized vitiligo","volume":"26","author":"Dwivedi","year":"2013","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41419-021-03592-0","article-title":"A protective role for autophagy in vitiligo","volume":"12","author":"Bastonini","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_67","first-page":"2064","article-title":"Relationship between autophagy of melanocytes in patients with vitiligo and clinical types","volume":"96","author":"Nie","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: A single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/jid.2013.540","article-title":"A quantitative increase in regulatory T cells controls development of vitiligo","volume":"134","author":"Chatterjee","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Ursini, F., Russo, E., Pellino, G., D\u2019Angelo, S., Chiaravalloti, A., De Sarro, G., Manfredini, R., and De Giorgio, R. (2018). Metformin and Autoimmunity: A \u201cNew Deal\u201d of an Old Drug. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01236"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature11862","article-title":"Metabolism of inflammation limited by AMPK and pseudo-starvation","volume":"493","author":"Hardie","year":"2013","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"274ra18","DOI":"10.1126\/scitranslmed.aaa0835","article-title":"Normalization of CD4+ T cell metabolism reverses lupus","volume":"7","author":"Yin","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMoa1411481","article-title":"Afamelanotide for Erythropoietic Protoporphyria","volume":"373","author":"Langendonk","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40262-016-0501-5","article-title":"Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders","volume":"56","author":"Minder","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"ref_76","first-page":"775","article-title":"A review and update on melanocyte stimulating hormone therapy: Afamelanotide","volume":"12","author":"Fabrikant","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/2013.jamadermatol.386","article-title":"The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo","volume":"149","author":"Grimes","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: A randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaad.2020.01.035","article-title":"Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians","volume":"82","author":"Toh","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2014.4951","article-title":"Indications and limitations of afamelanotide for treating vitiligo-reply","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Li, H., Zuo, J., and Tang, W. (2018). Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01048"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_83","first-page":"2386234","article-title":"Repigmentation of Tenacious Vitiligo on Apremilast","volume":"2017","author":"Huff","year":"2017","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e12923","DOI":"10.1111\/dth.12923","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: A case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","article-title":"Apremilast in Combination with Narrowband UVB in the Treatment of Vitiligo: A 52-Week Monocentric Prospective Randomized Placebo-Controlled Study","volume":"140","author":"Khemis","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jaad.2020.12.073","article-title":"Combination of apremilast and narrowband ultraviolet B light in the treatment of generalized vitiligo in skin phototypes IV to VI: A randomized split-body pilot study","volume":"85","author":"Kim","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_87","first-page":"e37180","article-title":"Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial","volume":"15","author":"Sharma","year":"2023","journal-title":"Cureus"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2021.03.028","article-title":"Repigmentation in a patient with vitiligo on crisaborole 2% ointment","volume":"11","author":"Tam","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1093\/bjd\/ljac092","article-title":"Successful treatment of vitiligo with crisaborole ointment: A report of two cases","volume":"188","author":"Sun","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/pde.14443","article-title":"Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: A novel treatment for recalcitrant pediatric vitiligo","volume":"38","author":"Marasca","year":"2021","journal-title":"Pediatr. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/j.jaad.2018.12.066","article-title":"Microneedling with Dermaroller 192 needles along with 5-fluorouracil solution in the treatment of stable vitiligo","volume":"81","author":"Kumar","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/ijdvl.IJDVL_386_16","article-title":"Efficacy of topical 5% fluorouracil needling in vitiligo","volume":"84","author":"Shashikiran","year":"2018","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/jocd.13152","article-title":"Evaluation of the additional effect of topical 5-fluorouracil to needling in the treatment of localized vitiligo","volume":"19","author":"Attwa","year":"2020","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/jocd.14388","article-title":"The clinical and pathological effectiveness of microneedling and topical 5-fluorouracil in vitiligo treatment: An association with matrix metalloproteinase 2 immunohistochemical expression","volume":"21","author":"Abdou","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/JCAS.JCAS_12_20","article-title":"Efficacy of Topical 5% 5-Fluorouracil with Needling versus 5% 5-Fluorouracil Alone in Stable Vitiligo: A Randomized Controlled Study","volume":"13","author":"Zahra","year":"2020","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jocd.12440","article-title":"Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo","volume":"17","author":"Mina","year":"2018","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/jocd.15616","article-title":"The efficacy of adding topical 5-fluorouracil to micro-needling in the treatment of vitiligo: A randomized controlled trial","volume":"22","author":"Pazyar","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/jocd.15481","article-title":"Efficacy and safety of micro-needling combined with topical 5-fluorouracil and excimer light vs. excimer light alone in treatment of non-segmental vitiligo: A comparative study","volume":"22","author":"Saad","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1365-4632.2007.03226.x","article-title":"Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo","volume":"46","author":"Sethi","year":"2007","journal-title":"Int. J. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/j.1524-4725.2011.02127.x","article-title":"Combination of microdermabrasion and 5-fluorouracil to induce repigmentation in vitiligo: An observational study","volume":"37","author":"Garg","year":"2011","journal-title":"Dermatol. Surg."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/jocd.12820","article-title":"Intradermal injection of Fluorouracil versus triamcinolone in localized vitiligo treatment","volume":"18","author":"Zohdy","year":"2019","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/09546634.2011.579084","article-title":"Treatment of localized non-segmental vitiligo with intradermal 5-flurouracil injection combined with narrow-band ultraviolet B: A preliminary study","volume":"23","author":"Shaaban","year":"2012","journal-title":"J. Dermatol. Treat."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/DSS.0000000000002736","article-title":"Trichloroacetic Acid in Different Concentrations: A Promising Treatment Modality for Vitiligo","volume":"47","author":"Nofal","year":"2021","journal-title":"Dermatol. Surg."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1346-8138.2010.01091.x","article-title":"Influence of trichloroacetic acid peeling on the skin stress response system","volume":"38","author":"Kimura","year":"2011","journal-title":"J. Dermatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e13532","DOI":"10.1111\/dth.13532","article-title":"Clinical evaluation of the efficacy of trichloroacetic acid 70% after microneedling vs intradermal injection of 5-fluorouracil in the treatment of nonsegmental vitiligo; A prospective comparative study","volume":"33","author":"Khater","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e15294","DOI":"10.1111\/dth.15294","article-title":"Microneedling combined with pimecrolimus, 5-fluorouracil, and trichloroacetic acid in the treatment of vitiligo: A comparative study","volume":"35","author":"Nofal","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40291-023-00672-z","article-title":"Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review","volume":"27","author":"Bialczyk","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.jidsp.5640189","article-title":"In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase","volume":"4","author":"Schallreuter","year":"1999","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4632.2008.03660.x","article-title":"From basic research to the bedside: Efficacy of topical treatment with pseudocatalase PC-KUS in 71 children with vitiligo","volume":"47","author":"Schallreuter","year":"2008","journal-title":"Int. J. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2230.2002.01142.x","article-title":"Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: An open, single-centre study","volume":"27","author":"Patel","year":"2002","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2133.2009.09252.x","article-title":"A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo","volume":"161","author":"Wittal","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1080\/09546634.2020.1729952","article-title":"Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase\/superoxide dismutase gel in children with limited vitiligo: A randomized controlled trial","volume":"33","author":"Alshiyab","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1001\/archopht.123.11.1609","article-title":"Periocular cutaneous pigmentary changes associated with bimatoprost use","volume":"123","author":"Galloway","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1034\/j.1600-0749.2000.130305.x","article-title":"Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys","volume":"13","author":"Prota","year":"2000","journal-title":"Pigment Cell Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/ijd.16307","article-title":"Assessment of prostaglandin F2-alpha (PGF2alpha) in lesional and nonlesional skin of vitiligo patients","volume":"61","author":"Nagui","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_116","first-page":"e13175","article-title":"Efficacy of topical latanoprost in the treatment of eyelid vitiligo: A randomized, double-blind clinical trial study","volume":"33","author":"Hosseini","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e14813","DOI":"10.1111\/dth.14813","article-title":"A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo","volume":"34","author":"Neinaa","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Silpa-Archa, N., Likittanasombat, S., Apinuntham, C., Pruksaeakanan, C., Charoenpipatsin, N., Chaiyabutr, C., and Wongpraparut, C. (2023). The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: A single-blind randomized controlled study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32591-8"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/jocd.13648","article-title":"Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study","volume":"20","author":"Kanokrungsee","year":"2021","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1007\/s00403-023-02700-8","article-title":"Efficacy of prostaglandin E2 versus prostaglandin F2 alpha assisted with narrowband-UVB in stable vitiligo","volume":"315","author":"Neinaa","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jid.2020.04.027","article-title":"Jak Inhibitors Reverse Vitiligo in Mice but Do Not Deplete Skin Resident Memory T Cells","volume":"141","author":"Azzolino","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.det.2019.08.005","article-title":"Phototherapy for Vitiligo","volume":"38","author":"Zubair","year":"2020","journal-title":"Dermatol. Clin."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/3\/191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:54:06Z","timestamp":1760028846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/3\/191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":122,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cimb47030191"],"URL":"https:\/\/doi.org\/10.3390\/cimb47030191","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}